Juanmonino
- A Delaware state court judge late Friday ruled that about 75,000 lawsuits against GSK (NYSE:GSK) and Pfizer (NYSE:PFE) over claims Zantac causes cancer can move forward as evidence brought by plaintiffs is legitimate.
- In her ruling, Superior Court Judge Vivian Medinilla wrote that juries are “the ultimate fact finders” and it would be inappropriate for a court to get in the middle of a debate over science.
- “This dispute presents a classic battle of the experts,” she wrote.
- Plaintiffs are claiming that ranitidine, the active ingredient in Zantac, could eventually contain the carcinogen NDMA. An FDA recall ordered Zantac from the market in 2020.
- Medinilla cited that recall in allowing experts to testify that NDMA can cause cancer and ranitidine can change and contain NDMA, Bloomberg reported.
- GSK said it will seek an appeal of the ruling. The British pharma added there is no “reliable evidence” ranitidine increases the risk of any type of cancer. They added that the ruling is inconsistent with the Federal Court’s Multidistrict Litigation ruling, which dismissed cases in December 2022.
